| Clinical assessment of HIV-associated lipodystrophy in an ambulatory population KA Lichtenstein, DJ Ward, AC Moorman, KM Delaney, B Young, ... Aids 15 (11), 1389-1398, 2001 | 547 | 2001 |
| The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a … J Eron, P Yeni, J Gathe, V Estrada, E DeJesus, S Staszewski, P Lackey, ... The Lancet 368 (9534), 476-482, 2006 | 467 | 2006 |
| Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised … J van Lunzen, F Maggiolo, JR Arribas, A Rakhmanova, P Yeni, B Young, ... The Lancet infectious diseases 12 (2), 111-118, 2012 | 386 | 2012 |
| Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study JJ Eron, B Clotet, J Durant, C Katlama, P Kumar, A Lazzarin, ... The Journal of infectious diseases 207 (5), 740-748, 2013 | 385 | 2013 |
| Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2 … JJ Eron, B Young, DA Cooper, M Youle, E DeJesus, ... The Lancet 375 (9712), 396-407, 2010 | 364 | 2010 |
| Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000–2006 B Young, CN Dao, K Buchacz, R Baker, JT Brooks Clinical Infectious Diseases 52 (8), 1061-1068, 2011 | 294 | 2011 |
| Trends in AIDS deaths, new infections and ART coverage in the top 30 countries with the highest AIDS mortality burden; 1990–2013 R Granich, S Gupta, B Hersh, B Williams, J Montaner, B Young, ... PloS one 10 (7), e0131353, 2015 | 241 | 2015 |
| Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial JJ Eron, JK Rockstroh, J Reynes, J Andrade-Villanueva, ... The Lancet infectious diseases 11 (12), 907-915, 2011 | 226 | 2011 |
| Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral … E DeJesus, B Young, JO Morales-Ramirez, L Sloan, DJ Ward, JF Flaherty, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 51 (2), 163-174, 2009 | 190 | 2009 |
| Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects JE Gallant, AE Rodriguez, WG Weinberg, B Young, DS Berger, ML Lim, ... The Journal of infectious diseases 192 (11), 1921-1930, 2005 | 187 | 2005 |
| Kidney disease in patients with HIV infection and AIDS J Winston, G Deray, T Hawkins, L Szczech, C Wyatt, B Young, KH Mayer Clinical Infectious Diseases 47 (11), 1449-1457, 2008 | 158 | 2008 |
| Undetectable equals untransmittable (U= U): awareness and associations with health outcomes among people living with HIV in 25 countries C Okoli, N Van de Velde, B Richman, B Allan, E Castellanos, B Young, ... Sexually transmitted infections 97 (1), 18-26, 2021 | 134 | 2021 |
| Immune reconstitution inflammatory syndrome: incidence and implications for mortality RM Novak, JT Richardson, K Buchacz, JS Chmiel, MD Durham, FJ Palella, ... Aids 26 (6), 721-730, 2012 | 121 | 2012 |
| Expert consensus statement on the science of HIV in the context of criminal law F Barré‐Sinoussi, SS Abdool Karim, J Albert, LG Bekker, C Beyrer, ... Journal of the International AIDS Society 21 (7), e25161, 2018 | 108 | 2018 |
| Mutations in a nonconserved sequence of the Tetrahymena ribozyme increase activity and specificity B Young, D Herschlag, TR Cech Cell 67 (5), 1007-1019, 1991 | 107 | 1991 |
| Early non-response to tenofovir DF (TDF)+ abacavir (ABC) and lamivudine (3TC) in a randomized trial compared to efavirenz (EFV)+ ABC and 3TC: ESS30009 unplanned interim analysis JE Gallant, AE Rodriguez, W Weinberg, B Young, D Berger, ML Lim, ... 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, 14-17, 2003 | 105 | 2003 |
| First large, multicenter, open-label study utilizing HLA-B* 5701 screening for abacavir hypersensitivity in North America B Young, K Squires, P Patel, E DeJesus, N Bellos, D Berger, ... Aids 22 (13), 1673-1675, 2008 | 104 | 2008 |
| Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus … KE Squires, B Young, E DeJesus, N Bellos, D Murphy, HH Zhao, LG Patel, ... AIDS 24 (13), 2019-2027, 2010 | 92 | 2010 |
| The HIV care continuum in Latin America: challenges and opportunities A Piñeirúa, J Sierra-Madero, P Cahn, RNG Palmero, EM Buitrago, ... The Lancet Infectious Diseases 15 (7), 833-839, 2015 | 89 | 2015 |
| Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results … O Ogbuagu, PJ Ruane, D Podzamczer, LC Salazar, K Henry, DM Asmuth, ... The Lancet HIV 8 (7), e397-e407, 2021 | 80 | 2021 |